Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229951 | 0.90 | NPC1 (0.47) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL6765328 | 0.85 | NPC1 (0.42) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL1150474 | 0.82 | NPC1 (0.43) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL28554259 | 0.79 | NPC1 (0.44) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL29014453 | 0.78 | NPC1 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL6270339 | 0.78 | — | — | |
| SCHEMBL5317101 | 0.78 | — | — | |
| SCHEMBL262815 | 0.78 | — | — | |
| SCHEMBL41312 | 0.76 | — | — | |
| SCHEMBL11411711 | 0.76 | RAB9A (0.41) | NPC1RAB9AKMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034061-B1 | Non-thrombogenic and anti-thrombogenic polymers | BIOINTERACTIONS LTD. (GB) | 2006-04-25 | — | — | US | claimed |
| EP-0896600-B1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | LUTHRA AJAY KUMAR (GB) | 2000-01-12 | — | — | EP | claimed |
| EP-0896600-A1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | Luthra, Ajay Kumar (GB) | 1999-02-17 | — | — | EP | claimed |
| WO-1997041164-A1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | LUTHRA AJAY KUMAR (GB) | 1997-11-06 | — | — | WO | claimed |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| US-11464788-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210401998-A1 | METHODS OF TREATING CYP2D6 ALTERNATIVE METABOLIZERS | NEKTAR THERAPEUTICS (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210393513-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2021-12-23 | — | — | US | disclosed |
| EP-2627639-B1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11129794-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2021-09-28 | — | — | US | disclosed |
| US-11033631-B2 | Methods of treating CYP2D6 alternative metabolizers | NEKTAR THERAPEUTICS (US) | 2021-06-15 | — | — | US | disclosed |
| US-6406687-B1 | POLYOXYALKYLENE ETHER, SULFATE, SULFONATE AND SULFAMATE AS ANTICOAGULANTS | BIOINTERACTIONS LTD. (GB) | 2002-06-18 | — | — | US | disclosed |
| US-6096798-A | COATING MATERIALS FOR MEDICAL DEVICES, SUCH AS TUBING OR CONNECTORS | BIOINTERACTIONS LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0896600-B1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | LUTHRA AJAY KUMAR (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999056126-A2 | IMMUNO-ADSORPTION MATRIX, A METHOD FOR THE PRODUCTION THEREOF, AND THE UTILIZATION THEREOF | AFFINA IMMUNTECHNIK GMBH (DE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0938340-A2 | METHOD FOR PREPARING BIOACTIVE POLYMERS | Bar Ilan University (IL) | 1999-09-01 | — | — | EP | disclosed |
| EP-0896600-A1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | Luthra, Ajay Kumar (GB) | 1999-02-17 | — | — | EP | disclosed |
| WO-1998002189-A2 | METHOD FOR PREPARING BIOACTIVE POLYMERS | BAR ILAN UNIVERSITY (IL) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997041164-A1 | NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS | LUTHRA AJAY KUMAR (GB) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129794-B2 | Chemically modified small molecules | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, ELANE | NPC1 1623/4885RAB9A 1241/4885KMT2A 1374/4885 |
| US-20210393513-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | NPC1 2189/4885RAB9A 1783/4885KMT2A 1395/4885 |
| US-11464788-B2 | Oligomer-corticosteroid conjugates | SERPINA6, NR3C2, NR3C1 | NPC1 585/4885RAB9A 4269/4885KMT2A 4574/4885 |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C2, NR3C1 | NPC1 585/4885RAB9A 4269/4885KMT2A 4574/4885 |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | POLM, OGG1, COPE | NPC1 2566/4885RAB9A 3926/4885KMT2A 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.